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Abstract: Purpose: Osteoporosis is a relevant problem after long term administration of unfractionated heparin (UFH) 
and low molecular weight heparin. Melagatran is a representative of a new group of direct thrombin inhibitors with 
comparable data in the prevention of thromboembolic events after orthopaedic surgery. The aim of our in vitro study was 
to investigate the effect of a direct thrombin inhibitor compared with dalteparin and UFH on human osteoblasts. 
Materials and Methods: Melagatran, dalteparin and UFH were added to primary osteoblast cultures in their therapeutic 
range and two decimal powers below and above. Cell number, protein synthesis, mitochondrial and alkaline phosphatase 
activity and collagen type I synthesis were evaluated. 
Results: Melagatran showed the least influence on protein synthesis and cell proliferation with a reduction of cell number 
to 83.5 ± 9% (p = 0.027) of the control group only in the highest investigated concentration after 15 days of incubation. 
Mitochondrial and alkaline phosphatase activity and collagen type I synthesis in osteoblasts incubated with melagatran 
and dalteparin showed similar patterns. UFH showed the most pronounced influence on cellular metabolism. 
Conclusions: Melagatran showed less inhibitory in vitro effects on human osteoblasts than dalteparin or UFH. The 
presented study gives first hints that direct thrombin inhibitors may help prevent heparin-induced negative effects on bone 
metabolism. 
Keywords: Direct thrombin inhibitor, dalteparin, heparin, osteoblasts, osteoporosis. 
INTRODUCTION 
  Anticoagulant therapy is capable of drastically reducing 
the incidence of thromboembolic events after orthopaedic 
and traumatologic interventions [1-3]. A relevant side effect 
of unfractionated heparin (UFH) and low molecular weight 
heparins is the induction of osteopenia during long-term 
therapy [4-6], which can progress to osteoporosis with the 
risk of pathological fractures [7, 8]. Shaugnessy et al. 
showed a 30% decrease of cancellous bone volume in a rat 
model after only 28 days of UFH administration [9]. 
Tinzaparin, a representative of the low molecular weight 
heparins (LMWH), reduced the bone mineral density by 
18.5% after an application of 32 days [10]. 
  The direct thrombin inhibitor ximelagatran is a member 
of a new group of anticoagulants, which can be administered 
orally in contrast to the heparins. After intake ximelagatran 
is converted to the active agent melagatran through 
dealkylation and dehydroxylation. 
  Clinical studies proved the effectiveness of melagatran 
during long-term prophylaxis of thromboembolic events [11, 
12]. 
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  Side effects of melagatran on bone metabolism have not 
been investigated yet. One of the most sensible markers for 
heparin-induced osteopenia is a loss in osteoblast number 
[13-15]. Therefore the aim of this study was to describe the 
effect of melagatran on human osteoblasts in vitro in 
comparison to conventional heparins, namely UFH and the 
LMWH dalteparin. Apart from the influence of the drugs on 
cell proliferation we also investigated parameters of 
osteoblast metabolism as mitochondrial activity, collagen 
production, alkaline phosphatase activity and protein 
synthesis. 
MATERIALS AND METHODS 
  Osteoblast cultures were derived from cancellous bone 
from six individuals (aged 63 – 78 years, males 3, females 3) 
harvested during total knee replacement according to a 
previously published procedure [15]. Bone metabolism 
disorders were excluded preoperatively by laboratory tests 
and bone density measurement (Lunar-DPXL, General 
Electric, Germany). 
Cell Culture 
  The cancellous bone was separated into fragments of 
approximately 1 mm
3 size, which were rinsed with 
phosphate buffered saline (PBS) until no fat droplets and 
erythrocytes were macroscopically visible in the supernatant 
anymore. Eight cancellous cubes were seeded on a Petri dish 
(BD Bioscience, Germany) and incubated with 8 ml of   
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medium (DMEM Ham’s F12 with 10% of fetal calf serum + 
penicillin + streptomycin, Gibco, Germany) which was 
renewed at 3 day intervals. Upon confluence of the cells, 
they were transferred to cell culture flasks (BD Bioscience, 
Germany) using 0.25% trypsin (Sigma, Germany). After two 
weeks the cells could be used for the investigations and were 
seeded onto 48-well plates (BD Bioscience, Germany) with a 
density of 2500 cells/well in 0.5 ml medium. 
  After adherence of the cells, the culture medium was 
renewed and melagatran, dalteparin, UFH, or PBS was 
added. Dosages of the drugs were referenced to the 
therapeutic plasma concentrations with additional dosages at 
two decimal powers above and beneath the latter (Fig. 1). 
  Media and substances were changed in two day intervals. 
Measurements were performed on the 15
th day after addition 
of the substances (n = 12 wells per concentration and timepoint). 
Cell Proliferation 
  Cell number was determined every second day (n = 6 
wells per concentration and timepoint). 
  Cells were rinsed twice with PBS and incubated with 
0.25% trypsin for 5 min. Total detachment was controlled 
microscopically before measuring cell concentration using a 
cell counter (CASY II, Schärfe Systems, Germany). 
Cell Vitality Test 
  Activity of mitochondrial dehydrogenase was determined 
to evaluate cell vitality. For this purpose a test kit (Cell 
Proliferation Kit II, Roche Molecular Biochemicals, 
Switzerland) based on the metabolization of XTT (sodium 
3´-[1-[(phenylamino)carbonyl]-3,4-tetrazolium]-bis(4-methoxy-6-
nitro)benzolsulfonic acid hydrate) was used [16, 17]. Two 
hours after the addition of 120 l reagent and 240 l medium 
per well, 300 l from each well were transferred to a 96-well 
plate and read off spectrophotometrically at 450 nm against a 
reference of 630 nm using an ELISA reader (Dynex 
Revelation 4.22, Microtek, Taiwan). 
Measurement of Protein Concentration 
  Due to the high amount of protein in FCS, cells were 
rinsed for three times and incubated with FCS-free medium 
plus substance 24 hours before measurement. After this 
period 150 l of supernatant of each well were transferred to 
a 96-well plate and mixed 1: 1 with reagent (BCA Protein 
Assay, Pierce, USA). After 30 minutes the protein value was 
 
Fig. (1). Presentation of the therapeutic plasma concentrations of the substances investigated (UFH 0.3 – 0.7 IU/ml [26], dalteparin 0.2 – 0.5 
IU/ml [9], melagatran 0.05 – 0.5 nmol/ml [12] and the tested concentrations. 
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determined against a standard curve of bovine standard 
albumin (0-512 g/ml BSA) at 630 nm. 
Measurement of Alkaline Phosphatase (ALP) Activity 
  After evaluation of the protein concentration the 
remaining medium was aspirated and the cells were rinsed 
with PBS. 500 l of reagent (37.5 parts by volume 0.5 M 
NaHCO3, 12.5 parts by volume 0.01 M MgCl2, 25 parts by 
volume distilled water and 25 parts by volume 0.1 M PNPP, 
p-nitrophenyl phosphate, Sigma, USA) were added. After an 
incubation of 8 h at 37 °C, the activity of ALP was 
determined photometrically at 405 nm against a standard 
curve. 
Measurement of Matrix Collagen Type I 
  The plates were rinsed three times with PBS and 
incubated overnight at 4 °C with anti-collagen type I rabbit 
polyclonal antibodies diluted 1: 150 (Chemicon, USA), and 
treated by the EnVision
TM method (DAKO, Denmark). After 
repeated washes with PBS, the wells were reacted with 
diaminobenzidine solution containing 0.01% H2O2. 
  The plates were scanned using the resolutions 600 x 600 
dots/inch and 8 bits/colour (red, green, blue). After 
separation of the magenta-coloured channel, representing the 
immunostaining [18], the mean greyscale value of each well 
was determined by defining the region of interest and 
calculating the histogram. All image operations were 
performed on an Intel
® Pentium
® M 715 processor using 
Corel Draw 10
®. 
Preliminary Tests 
  In order to determine the influence of the substances on 
the measuring procedure, all of the above-mentioned 
concentration and activity determinations were first 
conducted without cells. 
Statistical Analysis 
  All measurements were repeated three times under the same 
conditions, whereby two parallel sets were conducted at each 
time. Mean and standard deviations were determined for each 
group. Significance analysis was performed with the non-
parametric Mann-Whitney U test for independent samples. 
RESULTS 
  The preliminary tests showed that the substances added 
to the medium did not influence the results in the 
investigated concentration ranges. 
Proliferation Assay 
  UFH and dalteparin caused an increase of cellular 
proliferation up to the 2.3-fold, respectively 1.5-fold of the 
control group without substance at concentrations between 
0.05 and 5 U/ml (p < 0.001) (Fig. 2). 50 U/ml UFH inhibited 
cellular proliferation to 10 ± 3%, 50 U/ml dalteparin to 39 ± 
15% of the control group (p < 0.001 both) 
  In contrast to that melagatran only had an influence on 
osteoblast proliferation in the highest investigated 
concentration with a reduction of cell number to 84 ± 9% of 
the control group (p = 0.027). 
  UFH and dalteparin inhibited osteoblast proliferation 
from the fourth day on, melagatran from the sixth day on 
after application (Fig. 3). 
Mitochondrial Activity (Fig. 4) 
  UFH and dalteparin caused an increase of mitochondrial 
activity at 0.5 U/ml to 125% respectively 124% of the 
 
Fig. (2). Effect of melagatran, dalteparin and UFH on cell proliferation. Relative cell content per well on day 15 after incubation, 
standardized to the control group without substance in relation to the concentration of the substances investigated. (control = 1). Effect of a Direct Thrombin Inhibitor  The Open Orthopaedics Journal, 2011, Volume 5    55 
control group (p = 0.022 and p = 0.027). In contrast to that 
higher concentrations of UFH and dalteparin (50 U/ml) 
reduced cellular activity to 26 ± 2% (p < 0.001) respectively 
67 ± 10% of the control group (p = 0.003). Melagatran 
inhibited cellular activity at 5 and 50 nmol/ml to 77 ±15%  
(p = 0.04) respectively 57 ± 8% of the control group   
(p < 0.001). 
Protein Synthesis (Fig. 5) 
  At 50 U/ml UFH and dalteparin reduced osteoblast 
protein synthesis to 55 ± 5% (p < 0.001) respectively 68 
±12% (p = 0.013) of the control group without substances. In 
contrast to that melagatran had no influence on the protein 
synthesis of the cells in the investigated concentrations. 
 
Fig. (3). Cell proliferation (absolute cell numbers per well) under the influence of the highest investigated concentration (UFH and 
dalteparin; 50 IU/ml, melagatran: 50 nmol/ml). 
 
Fig. (4). Optical density according to the XTT-Test, standardized to the control group without substance in relation to the concentration of 
the substances investigated. (control = 1). 
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Alkaline Phosphatase Activity (Fig. 6) 
  Activity of alkaline phosphatase was reduced to 32 ± 3% 
of the control group by 50 U/ml UFH (p < 0.001). In 
comparison to that 50 U/ml dalteparin only caused a 
reduction to 70 ± 11% of the control group (p = 0.013). 50 
nmol/ml melagatran inhibited ALP activity to 66 ± 12% of 
the control group (p = 0.012). 
Collagen Type I Synthesis (Fig. 7) 
  UFH increased the collagen type I synthesis in a 
concentration dependent manner between 0.005 and 0.5 
U/ml up to the two-fold value of the control group at 0.5 
U/ml. In contrast to that higher concentrations of UFH   
(5 U/ml and 50 U/ml) lead to a decrease of collagen type I 
deposition (72 ± 57% (p = 0.056) respectively 9 ± 10%   
(p < 0.001) of the control group). Melagatran and dalteparin 
effected a reduction of collagen type I deposition at their 
highest in vitro concentrations also, but only to 46 ± 45%  
(p = 0.013) respectively 54 ± 10% (p < 0.001). 
DISCUSSION 
  Osteoblast number and function is crucial for the process 
of fracture healing, the integration of endoprosthetic 
implants but also for the permanent remodelling processes of 
bone. 
 
Fig. (5). Relative protein concentrations of the medium in relation to the concentration of the substances investigated. (control = 1). 
 
Fig. (6). Alkaline phosphatase activity of the osteoblasts, standardized to the control group without substance in relation to the concentration 
of the substances investigated. (control = 1). Effect of a Direct Thrombin Inhibitor  The Open Orthopaedics Journal, 2011, Volume 5    57 
  The decreased bone mineral density after or during 
heparin therapy results in a higher risk of fractures [7], in an 
inhibition of fracture healing [19] (Kock, Werther 2002) and 
may compromise the integration of endoprosthetic implants 
[20-22] In the present study we investigated for the first time 
the effects of a member of a new family of oral 
anticoagulants on human osteoblasts. Changes in osteoblast 
number and function were compared with changes under the 
influence of dalteparin und UFH. 
  Limitations of the study are the investigation of only one 
member of the group of direct thrombin inhibitors, 
melagatran, on the one hand and on the other hand the fact 
that an in vitro study can only mimic in vivo conditions but 
not entirely describe them. Furthermore the study focussed 
on osteoblasts and did not investigate osteoclast function or 
evaluate transcription factors. Therefore the results of our 
study can only be seen as promising first hints towards a 
possible advantage of direct thrombin inhibitors concerning 
osteometabolism. 
  In the investigated parameters cell number, activity of 
mitochondrial dehydrogenase, protein synthesis, collagen 
type I synthesis and activity of alkaline phosphatase 
melagatran showed similar or less impact on the osteoblasts 
than dalteparin and UFH in clinically relevant 
concentrations. 
  Heparins accumulate in bone and high substance 
concentrations around osteoblasts can be expected [8, 9]. 
Hence, the results obtained under the influence of the 10-fold 
and 100-fold therapeutical concentration of the substances 
are crucial for their clinical use. 
  In the highest investigated concentration (50 nmol/ml) 
melagatran only reduced the cell count to 84% of the control 
group after 15 days of incubation, whereas reduction of cell 
count was far more pronounced under the influence of 
dalteparin (39%, 50 U/ml) and UFH (10%, 50 U/ml). This 
loss in osteoblasts is to be held responsible for the 
development of heparin-induced osteopenia [10, 13, 14]. 
  In the present in vitro model negative effects of UFH on 
cellular proliferation and function could be seen in 
accordance with the literature. In contrast to that melagatran 
affected human osteoblasts to a lesser extent, comparable or 
even less than dalteparin. Based on the presented results 
advantages concerning the prevention of heparin-induced 
osteopenia, particularly during long term therapy, could be 
possible with the use of direct thrombin inhibitors. If this 
group can be used for long term anticoagulation in future 
still has to be elucidated. In a study with a 35-day period of 
intake of ximelagatran, being the first member of oral direct 
thrombin inhibitors, one patient showed a severe although 
reversible liver damage and ximelagatran was taken from the 
market - also since elevated liver enzymes had been reported 
as an adverse effect beforehand. (EXTEND Study, 
ClinicalTrials.gov Identifier NCT00206089) Since the 
effectiveness of melagatran in long term prophylaxis of 
thromboembolic events had already been shown [11, 12], the 
future replacement of subcutaneously injected substances by 
oral anticoagulants can be expected. The oral application is 
superior to subcutaneous therapy, on the one hand because of 
better patient acceptance [10] and on the other hand because 
of fewer side effects of the application itself [23, 24]. 
  The anticoagulatory potential of melagatran could be 
proven to be equal respectively better than that of LMWHs. 
The METHRO II study showed a reduction of incidence of 
deep venous thrombosis to 15.1% in the melagatran group 
compared to 28.2% in the dalteparin group (p < 0.001) [25]. 
The comparison with enoxaparin in a study with 2835 
patients, who underwent total knee or hip arthroplasty, also 
revealed a more pronounced reduction of the incidence of 
deep venous thrombosis in the melagatran group (20.3% 
 
Fig. (7). Relative collagen type I deposition per well, standardized to the control group without substance in relation to the concentration of 
the substances investigated. (control = 1). 58    The Open Orthopaedics Journal, 2011, Volume 5  Winkler et al. 
versus 26.6%, p < 0.001). Bleeding rates did not differ 
within groups [26]. 
  Particularly in patients with a reduced bone mineral 
density, e.g. after steroid therapy or because of renal insuf-
ficiency, hyperparathyroidism or idiopathic osteoporosis, 
prophylaxis of thromboembolism with substances with a 
smaller osteocatabolic potential than heparin is decisive. The 
presented study gives firsts hints that direct thrombin 
inhibitors could represent an alternative in this place. 
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